> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA OKs Apellis’ Syfovre for Geographic Atrophy
- URL: https://www.fdaweb.com/fda-oks-apellis-syfovre-for-geographic-atrophy/
- Published: 2023-02-17T12:00:00.000Z
- Updated: 2026-09-14T18:16:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5153814

FDA has approved Apellis Pharmaceuticals’ Syfovre (pegcetacoplan injection) to treat geographic atrophy (GA) secondary to age-related macular degeneration. The company [says](https://www.streetinsider.com/Globe+Newswire/FDA+Approves+SYFOVRE%E2%84%A2+%28pegcetacoplan+injection%29+as+the+First+and+Only+Treatment+for+Geographic+Atrophy+%28GA%29%2C+a+Leading+Cause+of+Blindness/21244256.html?ref=fdaweb.com) Syfovre is the only FDA-approved treatment for GA.

The approval was based on positive results from the Phase 3 OAKS and DERBY studies at 24 months across a broad and representative population of patients, Apellis says. It is approved for GA patients with or without subfoveal involvement and provides dosing flexibility with a dosing regimen of every 25 to 60 days.

Apellis says the most common adverse reactions were ocular discomfort, neovascular age-related macular degeneration, vitreous floaters, and conjunctival hemorrhage.